by on December 17, 2022

Gene Editing Market was valued at USD 3.1 billion in 2021 and is projected to reach USD 9.0 billion in 2029, growing at a significant CAGR of 14.3% during 2022-2029.

The factors driving the growth of Gene Editing Market includes increasing application of genomics in drug discovery, agriculture and identifying human genetic disorders, introduction of next-generation sequencing, growing prevalence of infectious diseases and cancer and improvements in the living standards. According to the report published by National Library of Medicine (NLB), the total cases of cancer in India was calculated around 0.589 million in 2011 and is expected to reach 0.934 million by the end of 2026, which will accelerate the demand for gene editing solutions in the approaching years. Moreover, technological innovations in gene-editing tools, rise in Government’s funding to the medical institutes for genetic research, expansion of the pharmaceutical industry, growing number of clinical trials for gene and stem cell therapies around the world and rapid urbanization, are some of the additional factors supplementing the Gene Editing Market size. In addition, the increasing investments by major companies on research and development, rising disposable incomes and growing population growth rates, are further contributing towards the market growth. 

Request a free sample of this report

However, growth of the Gene Editing Market is hindered due to growing concerns related to animal welfare.

The leading players operating in the market are Agilent Technologies, Allele Biotech, Bio Rad, CRISPR Therapeutics, Sangamo Therapeutics, Editas Medicine, Thermo Fisher Scientific, DNA Technologies, Intellia Therapeutics and Cellectis, among others.

Based on Technology, the Cluster Regularly Interspaced Short Palindromic Repeats (CRISPR) segment is predicted to hold the highest market share during the forecast period

Increasing number of clinical trials using gene-editing techniques for treating cancer, AIDS, and genetic diseases, are propelling growth of the segment.

Based on End-User, the Pharma-BioTech Companies segment is projected to lead the market over the forecast period

Growing focus by pharmaceutical companies on developing novel therapeutic treatments is pushing growth of the segment.

Based on Region, the North American region is anticipated to hold the highest market share during the forecast period

Presence of the leading players such as Sangamo Therapeutics, Editas Medicine and Thermo Fisher Scientific, rise in Government’s spending on the healthcare sector, increasing population growth rates and high per capita incomes, are some of the important factors augmenting the market growth in North American region.

Market Segmentation

Segmentation by Technology

  • Cluster Regularly Interspaced Short Palindromic Repeats (CRISPR)
  • Transcription Activator-Like Effector Nucleases (TALEN)
  • Zing Finger Nucleases (ZFN)
  • Others

Segmentation by Application

  • Animal Genetic Engineering
    o Therapeutic Application
    o Genetically Modified Organisms
  • Plant Genetic Engineering
  • Cell Line Engineering

Segmentation by End-User

  • Pharma-BioTech Companies
  • Academic Institutes & Research Center
  • Agrigenomic Companies
  • Contract Research Organization

Segmentation by Region

  • Asia Pacific
    • China
    • Japan
    • India
    • Rest of APAC
  • North America
    • United States of America
    • Canada
  • Europe
    • United Kingdom
    • Germany
    • France
    • Spain
    • Rest of Europe
  • RoW
    • Brazil
    • South Africa
    • Saudi Arabia
    • UAE

About GMI Research

GMI Research is a market research and consulting firm which provides market insights and intelligence across 12 major sectors helping our clients in making effective investment and business decisions.

Media Contact
Company Name: GMI RESEARCH
Contact Person: Sarah Nash
Phone: Europe – +353 1 442 8820; US – +1 860 881 2270
Address: Dublin, Ireland

Post in: health
Be the first person to like this.
Page generated in 0.2895 seconds with 18 queries and GZIP enabled on